Back to Journals » Nature and Science of Sleep » Volume 2

ZolpiMistTM: a new formulation of zolpidem tartrate for the short-term treatment of insomnia in the US

Authors Neubauer D

Published 10 May 2010 Volume 2010:2 Pages 79—84

DOI https://doi.org/10.2147/NSS.S6431

Review by Single-blind

Peer reviewer comments 2

David N Neubauer

Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Abstract: ZolpiMist™ is an oral spray formulation of the hypnotic compound zolpidem that was approved by the US Food and Drug Administration in 2008 with an indication for the shortterm treatment of insomnia characterized by difficulty with sleep initiation. It was developed by NovaDel Pharma, Inc. using their patented NovaMist™ spray technology. The recommended doses are 10 mg for adults and 5 mg for elderly and debilitated patients to be taken once daily immediately before bedtime. Each metered spray contains 5 mg of zolpidem. ZolpiMist was approved through the 505(b)(2) pathway, which allowed reference to pre-existing efficacy and safety data for the equivalent doses of zolpidem immediate-release tablets. Bioequivalence and pharmacokinetic characteristics were demonstrated in clinical studies with healthy adult and elderly subjects. ZolpiMist is being investigated for the possible indication of use during middleof-the-night awakenings when the patient has at least 4 hours available to remain in bed.
Keywords: ZolpiMist, zolpidem, oral spray formulation, hypnotic, insomnia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

A review of ramelteon in the treatment of sleep disorders

David N Neubauer

Neuropsychiatric Disease and Treatment 2008, 4:69-79

Published Date: 8 February 2008

Readers of this article also read:

Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK

Gelhorn HL, Poon JL, Davies EW, Paczkowski R, Curtis SE, Boye KS

Patient Preference and Adherence 2015, 9:1611-1622

Published Date: 9 November 2015

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Acquired hemophilia A: emerging treatment options

Janbain M, Leissinger CA, Kruse-Jarres R

Journal of Blood Medicine 2015, 6:143-150

Published Date: 8 May 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Fluorescence resonance energy transfer-based real-time polymerase chain reaction method without DNA extraction for the genotyping of F5, F2, F12, MTHFR, and HFE

Martinez-Serra J, Robles J, Nicolàs A, Gutierrez A, Ros T, Amat JC, Alemany R, Vögler O, Abelló A, Noguera A, Besalduch J

Journal of Blood Medicine 2014, 5:99-106

Published Date: 25 June 2014

Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A

Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S

Neuropsychiatric Disease and Treatment 2014, 10:865-867

Published Date: 16 May 2014